Literature DB >> 11170875

Ischaemia/reperfusion contributes to colonic injury following experimental aortic surgery.

P U Reber1, M Peter, A G Patel, E Stauffer, G Printzen, D Mettler, H Hakki, H W Kniemeyer.   

Abstract

OBJECTIVES: ischaemia of the colon is an important complication of abdominal aortic aneurysm (AAA) repair. The aim of this animal study was to investigate the effect of sequential ischaemia and reperfusion on sigmoid mucosal pO2 and its association with local ET-1 release.
MATERIAL AND METHODS: twelve pigs underwent colonic ischaemia followed by complete reperfusion. Six other animals were sham controls. A Clark-type microcatheter was used for continuous mucosal pO2 measurements. Serial systemic and inferior mesenteric vein blood samples were obtained for determination of ET-1 concentration. Neutrophil extravasation was assessed by tissue myeloperoxidase (MPO) activity.
RESULTS: arterial occlusion was associated with a gradual decrease of mucosal pO2 and local release of ET-1. After restoration of blood flow, mucosal pO2 returned to near baseline values, whereas ET-1 reached its maximum concentration during the reperfusion period. MPO activity was significantly increased.
CONCLUSIONS: colonic ischaemia and reperfusion causes neutrophil extravasation and local ET-1. Copyright 2001 Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170875     DOI: 10.1053/ejvs.2000.1264

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  2 in total

1.  Pyrrolidine dithiocarbamate reduces ischemia-reperfusion injury of the small intestine.

Authors:  Ismail H Mallick; Wen-Xuan Yang; Marc C Winslet; Alexander M Seifalian
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  Gut barrier dysfunction as detected by intestinal luminal microdialysis.

Authors:  Erik Solligård; Ingebjørg S Juel; Karin Bakkelund; Harald Johnsen; Ola D Saether; Jon Erik Grønbech; Petter Aadahl
Journal:  Intensive Care Med       Date:  2004-02-28       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.